Company: MBIO
Filing Date: 2025-04-01
Form Type: 424B3
Source: 0001104659-25-030657
Chunk: 254

Company: MUSTANG BIO, INC.
Filing Date: 2025-04-01
Form: 424B3
Chunk 254
---
ging transactions, and other inherently speculative transactions.

Additionally, you may not discuss
material, nonpublic information about a Company with anyone outside the Company. This prohibition covers spouses, family members, friends,
business associates, or persons with whom we are doing business (except to the extent that such persons are covered by a non-disclosure
agreement and the discussion is necessary to accomplish a business purpose of a Company). You may not participate in “chat room”
or other electronic discussion groups on the Internet concerning activities of a Company or other companies with which the Companies do
business, even if you do so anonymously. You may never recommend to another person that he or she buy or sell a Company stock.

Although this is by no means
an exhaustive list, information about the following items may be considered to be Inside Information until it is publicly disseminated:

| a) | regulatory developments, including developments with the United States Food and Drug Administration and Drug Enforcement Administration; |

​

<div align='center'>3</div>

​

| b) | clinical developments; |

| c) | financial results or forecasts; |

| d) | major new products or processes; |

| e) | establishment of, or developments in, strategic partnerships, joint ventures, or similar collaborations; |

| f) | communications with government agencies; |

| g) | strategic plans; |

| h) | potential mergers, acquisitions, tender offers, or the sale of assets of a Company or a subsidiary thereof; |

| i) | significant write-offs; |

| j) | potential acquisitions of additional product candidates or technology; |

| k) | notice of issuance of patents or the acquisition of other material intellectual property rights; |

| l) | significant changes or developments in the biopharmaceutical industry or technological innovations; |

| m) | new major contracts, orders, suppliers, customers, or finance sources, or the loss thereof; |

| n) | significant changes or developments in supplies; |

| o) | significant pricing changes; |

| p) | events regarding a Company’s securities (e.g., defaults on senior securities, call of securities for redemption, repurchase plans, stock splits, public or private equity/debt offerings, or changes in a Company’s dividend policies or amounts); |

| q) | significant changes in control or senior management; |

| r) | significant changes in compensation policies; |

| s) | bankruptcies or receiverships; |

| t) | actual or threatened major litigation, or a major development in or